Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106700 | 0.93 | CHRM3 (0.43) | HPGDCHRM3CHRM2CHRM1 | |
| SCHEMBL5106998 | 0.92 | CHRM3 (0.45) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5103245 | 0.89 | HPGD (0.43) | HPGDCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL5103798 | 0.88 | CHRM3 (0.44) | HPGDCHRM3 | |
| SCHEMBL5103241 | 0.87 | CHRM3 (0.38) | HPGDCHRM3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5099118 | 0.85 | CHRM3 (0.49) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5113733 | 0.85 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5103759 | 0.84 | CHRM3 (0.41) | HPGDCHRM3SMN1; SMN2NPC1AKR1C3 | |
| SCHEMBL5106874 | 0.84 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5113237 | 0.83 | FABP4 (0.41) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | HPGD 1575/4885CHRM3 1/4885CYP1A2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.